ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 11/14/22

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022. Webcast and Conference Call and Details Inv...

The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this event. For further details see: Arrowhead Pharmaceuticals (ARWR) Presents at AHA Scientific Sessions 2022

Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK an...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) has sold royalty interest in Amgen's ( NASDAQ: AMGN ) olpasiran to Royalty Pharma ( NASDAQ: RPRX ) for $250M in cash upfront plus up to $160M in additional payments contingent on the achievement of certain clinical, re...

- Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease - Arrowhead retains rights to $400 million in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement Arrowhead ...

Summary Arrowhead's partner Amgen reported positive phase 2 results of olpasiran in patients with elevated Lp[a]. Efficacy of the highest doses is near the maximum with 97% absolute reduction in Lp[a] concentration. Olpasiran was safe and well tolerated. Lp[a] is a genetic...

- ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia - ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mi...

Summary My portfolio, built specifically for my retirement ~20+ years from now, invested a new large position in a beaten down big tech stock. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a...

- Company will host a virtual analyst and investor event on November 9, 2022 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present interim clinical data from the ongoing SHASTA-2 Phase 2 study of ARO-APOC3 in patients with severe hypertriglyceridemia...

Summary My portfolio, built specifically for my retirement ~20+ years from now, had a crushing September, along with the rest of the market, in spite of amazing Petrobras dividends. Making monthly contributions, even though they seem small at the time, makes all the difference in ...